LDR also improves systemic metabolic parameters, including dyslipidemia and insulin resistance, through mechanisms such as enhanced protein kinase B activation and Nrf2-mediated antioxidant responses, although its efficacy is limited by a defined therapeutic window [158]. The gene discussed is AKT1; the disease is Insulin resistance.